Online citations, reference lists, and bibliographies.
← Back to Search

N‐trimethyl Chitosan Nanoparticles And CSKSSDYQC Peptide: N‐trimethyl Chitosan Conjugates Enhance The Oral Bioavailability Of Gemcitabine To Treat Breast Cancer

Guanyu Chen, D. Svirskis, W. Lu, Man Ying, Y. Huang, J. Wen
Published 2018 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
&NA; Gemcitabine is a nucleoside analogue effective against a number of cancers. However, the full potential of this drug has not been realised, in part due to low oral bioavailability and frequent dosing requirements. This study reports the synthesis, in‐vitro, ex‐vivo and in‐vivo evaluation of trimethyl chitosan (TMC) ‐ CSKSSDYQC (CSK) peptide conjugates capable of enhancing the oral bioavailability of gemcitabine due to the ability to target intestinal goblet cells and promote intestinal cellular uptake. TMC was synthesized by a novel two‐step methylation method to improve quanternization and yield. The CSK‐TMC conjugates were prepared by ionic gelation to achieve particles sized at 173.6 ± 6.8 nm, zeta potential of +18.5 ± 0.2 mV and entrapment efficiency of 66.4 ± 0.1%, capable of sustained drug release. By encapsulating gemcitabine into CSK‐TMC conjugates, an increased amount of drug permeated through porcine intestinal epithelial membranes compared with the unconjugated TMC nanoparticles (NPs). The rate of cellular uptake of drug loaded conjugates into HT29‐MTX‐E12 intestinal goblet cells, was time‐ and concentration‐dependant. The conjugates underwent active transport associated with adsorptive mediated, clathrin and caveolae mediated endocytosis. In cellular transport studies, drug loaded conjugates had greater drug transport capability compared with drug solution and TMC NPs over the co‐cultured Caco‐2/HT29‐MTX‐E12 cell monolayer. The drug loaded conjugates exhibited electrostatic interaction with the intestinal epithelial cells. Both P‐glycoprotein (P‐gp) and multiple resistance protein‐2 (MRP2) efflux affected the cellular transport of the conjugates. Importantly, during the pharmacokinetic studies, the orally administrated drug loaded into TMC NPs showed an improved oral bioavailability of 54.0%, compared with gemcitabine solution of 9.9%. Notable, the CSK‐TMC conjugates further improved oral bioavailability to 60.1% and reduced the tumour growth rate in a BALB/c nude mouse model, with a 5.1‐fold and 3.3‐fold reduction compare with the non‐treated group and gemcitabine solution group. Furthermore, no major evidence of toxicity was discernible on histologic studies of selected organs. In conclusion, the presented CSK‐TMC conjugates and TMC nanoparticles both significantly improve the oral bioavailability of gemcitabine and have the potential for the treatment of breast cancer.
This paper references
Zeta potential in colloid science : principles and applications
R. Hunter (1981)
10.1002/(SICI)1520-6017(200001)89:1<63::AID-JPS7>3.0.CO;2-6
Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: permeabilities via diffusion, inside- and outside-directed carrier-mediated transport.
C. Hilgendorf (2000)
10.1016/S0168-3659(01)00517-X
Factors affecting protein release from alginate-chitosan coacervate microcapsules during production and gastric/intestinal simulation.
G. Vandenberg (2001)
10.1111/jphp.12470
Development and validation of a stability indicating isocratic HPLC method for gemcitabine with application to drug release from poly lactic‐co‐glycolic acid nanoparticles and enzymatic degradation studies
Guanyu Chen (2015)
10.3322/caac.20107
Global cancer statistics
A. Jemal (2011)
10.1081/BIO-120023160
Encapsulating Protein into Preformed Liposomes by Ethanol‐Destabilized Method
Ching-Hua Wang (2003)
10.1080/03639040701484593
PLGA nanoparticles for the oral delivery of 5-Fluorouracil using high pressure homogenization-emulsification as the preparation method and in vitro/in vivo studies.
X. Li (2008)
10.1515/9783111576855-016
K
Martin P. Catherwood (1824)
N- trimethyl chitosan nanoparticles as a vitamin carrier system, Food Hydrocoll
D. de Britto (2012)
10.1023/A:1011919003030
Correlation Between Oral Drug Absorption in Humans, and Apparent Drug Permeability in TC-7 Cells, A Human Epithelial Intestinal Cell Line: Comparison with the Parental Caco-2 Cell Line
Marie-Catherine Grès (2004)
10.1007/S12195-011-0198-3
Chemotherapeutic Engineering: Concept, Feasibility, Safety and Prospect—A Tribute to Shu Chien’s 80th Birthday
S. Feng (2011)
10.2147/IJN.S26365
Chitosan–Pluronic nanoparticles as oral delivery of anticancer gemcitabine: preparation and in vitro study
H. Hosseinzadeh (2012)
Insulinloaded nanoparticles based on N-trimethyl chitosan: in vitro (Caco-2 model) and ex vivo (excised rat jejunum
G. Sandri (2010)
Absorption-enhancing mechanism of EDTA
M. Tomita (1996)
10.1016/j.biomaterials.2011.10.075
Goblet cell-targeting nanoparticles for oral insulin delivery and the influence of mucus on insulin transport.
Y. Jin (2012)
10.1016/j.biomaterials.2009.01.057
The uptake and intracellular fate of PLGA nanoparticles in epithelial cells.
Malgorzata S Cartiera (2009)
10.1016/J.JCONREL.2007.05.037
Preparation and evaluation of nanoparticles made of chitosan or N-trimethyl chitosan and a cisplatin-alginate complex.
S. Cafaggi (2007)
10.1023/A:1012160102740
Chitosans as Absorption Enhancers for Poorly Absorbable Drugs 2: Mechanism of Absorption Enhancement
N. G. Schipper (2004)
Huygevoort, Assessment of Acute Oral Toxicity with Ro 26-7624/000 (EGCG) in the Rat (Acute Toxic Class Method)
E. Wolz (2001)
10.1016/J.BIOMATERIALS.2004.07.050
Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs.
K. Y. Win (2005)
Cellular uptake of dietary flavonoid quercetin 4'-beta-glucoside by sodium-dependent glucose transporter SGLT1.
R. A. Walgren (2000)
10.1126/scitranslmed.3005872
Cancer Nanomedicine: From Drug Delivery to Imaging
E. K. Chow (2013)
10.3923/IJCR.2009.95.104
Clove (Syzygium aromaticum) Extract Potentiates Gemcitabine Cytotoxic Effect on Human Cervical Cancer Cell Line
A. Hussain (2009)
10.1016/J.FOODHYD.2011.09.002
N,N,N-trimethyl chitosan nanoparticles as a vitamin carrier system
D. Britto (2012)
10.1097/00001813-199512006-00002
Preclinical characteristics of gemcitabine
W. Plunkett (1995)
10.1016/j.biomaterials.2011.08.041
Synergistic effect of folate-mediated targeting and verapamil-mediated P-gp inhibition with paclitaxel -polymer micelles to overcome multi-drug resistance.
Feihu Wang (2011)
10.1208/s12249-010-9390-3
Insulin-Loaded Nanoparticles Based on N-Trimethyl Chitosan: In Vitro (Caco-2 Model) and Ex Vivo (Excised Rat Jejunum, Duodenum, and Ileum) Evaluation of Penetration Enhancement Properties
G. Sandri (2010)
10.1021/mp400685v
Mechanism study of cellular uptake and tight junction opening mediated by goblet cell-specific trimethyl chitosan nanoparticles.
J. Zhang (2014)
10.1021/JS9504604
Absorption-enhancing mechanism of EDTA, caprate, and decanoylcarnitine in Caco-2 cells.
M. Tomita (1996)
10.1016/S1359-6446(03)02873-3
In vitro trans-monolayer permeability calculations: often forgotten assumptions.
K. Youdim (2003)
Human Physiology : From Cells to Systems
L. Sherwood (1989)
10.1016/j.biomaterials.2009.02.045
Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel.
S. Feng (2009)
10.1023/A:1013018111829
Gliadin Nanoparticles as Carriers for the Oral Administration of Lipophilic Drugs. Relationships Between Bioadhesion and Pharmacokinetics
M. A. Arangoa (2004)
10.1039/B204455M
FTIR study of adsorption and photochemistry of amide on powdered TiO2 : Comparison of benzamide with acetamide
Li-Fen Liao (2002)
Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine).
L. W. Hertel (1990)
10.1211/0022357991776976
Enhanced Permeability of Insulin across the Rat Intestinal Membrane by Various Absorption Enhancers: Their Intestinal Mucosal Toxicity and Absorption‐enhancing Mechanism of n‐Lauryl‐β‐D‐maltopyranoside
T. Uchiyama (1999)
10.1016/j.addr.2012.11.005
Pharmaceutical nanotechnology for oral delivery of anticancer drugs.
L. Mei (2013)
10.1016/S0144-8617(98)00009-5
Preparation and NMR characterization of highly substitutedN-trimethyl chitosan chloride
A. Sieval (1998)
Clinical e ffi cacy of intra - arterial pharmacokinetic chemotherapy with 5 - fl uorouracil , CDDP , gemcitabine , and angiotensin - II in patients with advanced pancreatic cancer
H. Kamimura
10.2147/NANO.2006.1.2.117
Chitosan nanoparticles for oral drug and gene delivery
Katherine Bowman (2006)
10.1111/j.1440-1681.2006.04492.x
EFFECTS OF GENETIC POLYMORPHISMS OF CYP3A4, CYP3A5 AND MDR1 ON CYCLOSPORINE PHARMACOKINETICS AFTER RENAL TRANSPLANTATION
Yong-fang Hu (2006)
10.1007/s11095-009-9896-0
Identification of Novel Specific and General Inhibitors of the Three Major Human ATP-Binding Cassette Transporters P-gp, BCRP and MRP2 Among Registered Drugs
P. Matsson (2009)
Clinical efficacy of intra-arterial pharmacokinetic chemotherapy with 5-fluorouracil, CDDP, gemcitabine, and angiotensin-II in patients with advanced pancreatic cancer.
T. Ishikawa (2007)
10.1039/9781847558435
New Frontiers in Colloid Science : A celebration of the career of Brian Vincent
S. Biggs (2008)
10.1016/j.ejps.2014.04.014
Enhanced bioavailability and intestinal uptake of Gemcitabine HCl loaded PLGA nanoparticles after oral delivery.
G. Joshi (2014)
10.1016/0021-9681(60)90137-5
Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide
C. Zubrod (1960)
10.2174/138161208784246216
Novel approaches to deliver gemcitabine to cancers.
L. H. Reddy (2008)
10.1016/S0169-409X(01)00180-6
Chitosan and its derivatives as intestinal absorption enhancers.
M. Thanou (2001)
10.1007/s11095-007-9367-4
Alginate/Chitosan Nanoparticles are Effective for Oral Insulin Delivery
B. Sarmento (2007)
10.1021/jp110601w
Conformational structure of tyrosine, tyrosyl-glycine, and tyrosyl-glycyl-glycine by double resonance spectroscopy.
A. Abo-riziq (2011)
10.1016/j.drudis.2012.03.019
An overview of natural polymers for oral insulin delivery.
T. Sonia (2012)
10.1039/C6RA02371A
Targeted solid lipid nanoparticles with peptide ligand for oral delivery of atorvastatin calcium
Qingqing Tian (2016)
10.1345/aph.1E068
Use of Verapamil as a Potential P-Glycoprotein Inhibitor in a Patient with Refractory Epilepsy
M. Summers (2004)
ff ects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs
S.-S. Feng (2009)
10.1016/j.jconrel.2014.05.029
Sustained-release from nanocarriers: a review.
Jayaganesh V. Natarajan (2014)
10.1081/DRT-120028238
Effect of Freeze-Drying Process Conditions on the Stability of Nanoparticles
M. Choi (2004)
10.1097/00000539-199903000-00009
Remifentanil administration during monitored anesthesia care: are intermittent boluses an effective alternative to a continuous infusion?
M. S. Sá Rêgo (1999)
10.1093/JNCI/86.20.1530
Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients.
B. Lund (1994)
10.3329/IJPLS.V2I3.15457
Drug Delivery to The Brain Using Polymeric Nanoparticles: A Review
Bhatt Neha (2013)
10.1016/j.jbiotec.2008.01.021
Identification of a peptide sequence that improves transport of macromolecules across the intestinal mucosal barrier targeting goblet cells.
S. K. Kang (2008)
10.3109/03639045.2012.756512
Deformable liposomes by reverse-phase evaporation method for an enhanced skin delivery of (+)-catechin
Guanyu Chen (2014)
10.1023/A:1025415616592
CASE REPORT: Fatal Cholestatic Liver Failure Associated with Gemcitabine Therapy
K. Robinson (2004)
10.1515/9783111576855-015
J
Seguin Hen (1824)
10.1023/A:1019854327540
Comparative Uptake Studies of Bioadhesive and Non-Bioadhesive Nanoparticles in Human Intestinal Cell Lines and Rats: The Effect of Mucus on Particle Adsorption and Transport
I. Behrens (2004)
10.1016/0006-291X(91)91647-U
Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells.
P. Artursson (1991)
10.1016/J.JCONREL.2003.10.001
Absorption enhancers in pulmonary protein delivery.
Alamdar Hussain (2004)
Phase II study of gemcitabine ( 2 ′ , 2 ′ - di fl uorodeoxycytidine ) in previously treated ovarian cancer patients
O. P. Hansen Lund (2008)
10.1016/S0928-0987(99)00032-9
Chitosans as absorption enhancers of poorly absorbable drugs. 3: Influence of mucus on absorption enhancement.
N. G. Schipper (1999)
10.1200/JCO.2000.18.17.3068
Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.
H. von der Maase (2000)
10.1074/jbc.272.27.16838
Role of Heparan Sulfate Proteoglycans in the Uptake and Degradation of Tissue Factor Pathway Inhibitor-Coagulation Factor Xa Complexes*
G. Ho (1997)
10.1016/S0140-6736(05)61503-6
T
D. Davies (1998)
10.1007/s10856-008-3659-z
Trimethyl chitosan and its applications in drug delivery
V. Mourya (2009)
10.1016/J.TOXLET.2005.07.001
In vitro cytotoxicity assays: comparison of LDH, neutral red, MTT and protein assay in hepatoma cell lines following exposure to cadmium chloride.
G. Fotakis (2006)
Preparation and Characterization of Trimethyl Chitosan Nanospheres Encapsulated with Tetanus Toxoid for Nasal Immunization Studies
M. Zarifpour (2013)
10.1111/jphp.12313
Mucoadhesive polymers‐based film as a carrier system for sublingual delivery of glutathione
Guanyu Chen (2015)
10.1213/01.ane.0000197778.57615.1a
A Randomized Comparison of Programmed Intermittent Epidural Bolus with Continuous Epidural Infusion for Labor Analgesia
C. Wong (2006)
10.1016/S0378-5173(02)00486-6
Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo.
Yan Pan (2002)
10.1155/2012/632698
Antifungal Activity of Chitosan Nanoparticles and Correlation with Their Physical Properties
Ling Yien Ing (2012)
10.1155/2015/537560
Utilization of Glycosaminoglycans/Proteoglycans as Carriers for Targeted Therapy Delivery
S. Misra (2015)
Gemcitabine-induced liver fibrosis in a patient with pancreatic cancer.
M. Saif (2007)
10.1016/j.ijbiomac.2010.01.010
Comparison of chitosan/siRNA and trimethylchitosan/siRNA complexes behaviour in vitro.
V. Dehousse (2010)
10.1016/j.biomaterials.2012.07.063
Size-dependent absorption mechanism of polymeric nanoparticles for oral delivery of protein drugs.
Chunbai He (2012)
ff ects of genetic polymorphisms of CYP 3 A 4 , CYP 3 A 5 and MDR 1 on cyclosporine pharmacokinetics after renal transplantation
W. Qiu (2006)



This paper is referenced by
10.2174/1389203721666200210103841
The Brief Analysis of Peptide-combined Nanoparticle: Nanomedicine's Unique Value.
Jiemin Wang (2020)
10.1016/j.carbpol.2020.116594
Chitosan: A promising therapeutic agent and effective drug delivery system in managing diabetes mellitus.
S. Sarkar (2020)
10.1016/j.ijbiomac.2019.02.005
Chitosan coated human serum albumin nanoparticles: A promising strategy for nose-to-brain drug delivery.
V. Piazzini (2019)
Targeting MRP2 in HepG2 Cells Using the CRISPR-Cas9 System to Reverse Oxaliplatin Resistance
Ying Zou (2019)
10.1016/j.jconrel.2020.01.028
Polyester based polymeric nano and microparticles for pharmaceutical purposes: A review on formulation approaches.
Fatima Molavi (2020)
10.1002/jcp.29781
Coinhibition of S1PR1 and GP130 by siRNA‐loaded alginate‐conjugated trimethyl chitosan nanoparticles robustly blocks development of cancer cells
N. Rostami (2020)
10.1016/J.EURPOLYMJ.2020.110016
Quaternary ammonium salts of chitosan. A critical overview on the synthesis and properties generated by quaternization
Bianca-Iustina Andreica (2020)
10.1016/j.ijbiomac.2018.12.182
Development of mutlifunctional nanoparticles self-assembled from trimethyl chitosan and fucoidan for enhanced oral delivery of insulin.
Li-Chu Tsai (2019)
10.1080/10837450.2020.1787441
Multifunctional nanoparticles of paclitaxel and cyclodextrin–polypeptide conjugates with in vitro anticancer activity
Sun Yusheng (2020)
10.3389/fmicb.2020.02098
Emerging Molecular Prospective of SARS-CoV-2: Feasible Nanotechnology Based Detection and Inhibition
S. Patra (2020)
10.1016/j.jconrel.2020.04.006
Overcoming the intestinal barrier: A look into targeting approaches for improved oral drug delivery systems.
Yining Xu (2020)
10.1016/J.CARBPOL.2019.115004
Advances in chitosan-based nanoparticles for oncotherapy.
E. Zhang (2019)
10.1016/j.addr.2020.05.007
Systemic delivery of peptides by the oral route: Formulation and medicinal chemistry approaches.
D. Brayden (2020)
10.1039/c9bm01378d
Biomimetic and bioinspired strategies for oral drug delivery.
Xiankang Hu (2019)
10.1016/j.nantod.2020.100961
Nanomedicine strategies to target coronavirus
M. Heinrich (2020)
10.7150/JBM.27148
Poly(lactic-co-glycolic acid) based double emulsion nanoparticle as a carrier system to deliver glutathione sublingually
Guanyu Chen (2018)
10.1016/j.biomaterials.2020.120157
A bubble bursting-mediated oral drug delivery system that enables concurrent delivery of lipophilic and hydrophilic chemotherapeutics for treating pancreatic tumors in rats.
Kuan-Hung Chen (2020)
10.1016/j.bcp.2019.06.013
Mechanisms of Gemcitabine Oral Absorption as Determined by In Situ Intestinal Perfusions in Mice.
Brian R. Thompson (2019)
10.1007/s00216-018-1319-9
Quantification of BSA-loaded chitosan/oligonucleotide nanoparticles using reverse-phase high-performance liquid chromatography
Chun Y Wong (2018)
10.1016/j.jddst.2020.101607
Mechanisms for oral absorption enhancement of drugs by nanocrystals
Jia-li Liu (2020)
10.1039/c9bm01604j
Collaborative assembly of doxorubicin and galactosyl diblock glycopolymers for targeted drug delivery of hepatocellular carcinoma.
J. Li (2019)
10.1016/j.ijbiomac.2020.03.148
Advances and applications of chitosan-based nanomaterials as oral delivery carriers: A review.
Xuqian Lang (2020)
10.3390/molecules23102661
Chitosan-Based Nanomaterials for Drug Delivery
Jianghua Li (2018)
Semantic Scholar Logo Some data provided by SemanticScholar